Feb 24 2012
SANUWAVE Health, Inc. (OTCBB: SNWV) has entered into a two-year exclusive distribution agreement with CAN-med Healthcare, a division of IMP Group Limited, to distribute the Company's dermaPACE® device throughout Canada. The dermaPACE device utilizes the Company's Pulsed Acoustic Cellular Expression (PACE®) technology for acute and chronic wound healing. The agreement includes annual minimum purchase requirements and allows for term extensions.
“dermaPACE is approved in Canada to treat a wide range of acute and chronic wounds. CAN-med Healthcare's initial focus will be on the treatment of diabetic foot ulcers, leveraging positive data from our recently completed pivotal clinical trial investigating dermaPACE to treat these debilitating and costly ulcers.”
Established over 40 years ago, CAN-med Healthcare has a reputation as a service-driven company with a commitment to improving healthcare and a thorough understanding of the market and their customers' needs. CAN-med Healthcare strives to put in place proven, cost-effective solutions that help Canadians live longer and healthier lives, and they distribute a diverse range of medical offerings, including wound care and trauma products that complement dermaPACE.
Stephen McDonald, CAN-med Healthcare's Vice President and General Manager, commented, "dermaPACE technology is a great fit for us, as it builds upon our legacy of bringing new, leading edge products to the Canadian market. As a company, we're always looking for exclusive partnerships that involve innovative, clinically validated and differentiated technology that can improve patient outcomes and overall delivery of care. We believe we've met these objectives with SANUWAVE."
"It is the mandate of every health department in Canada to improve care to all Canadians, while staying within the confines of increasingly tighter budgets," added Jim Ritcey, Director of Sales and Marketing for CAN-med Healthcare. "We believe that dermaPACE, with its proven safety and efficacy, combined with its potential to reduce costs associated with chronic wound care, could truly be a 'game changer' in the battle against chronic wounds."
"CAN-med Healthcare is a welcome addition to our growing distribution network for PACE technology, and they have the distinct honor of being the first PACE distributor in North America," stated Christopher M. Cashman, President and CEO of SANUWAVE. "dermaPACE is approved in Canada to treat a wide range of acute and chronic wounds. CAN-med Healthcare's initial focus will be on the treatment of diabetic foot ulcers, leveraging positive data from our recently completed pivotal clinical trial investigating dermaPACE to treat these debilitating and costly ulcers."
Mr. Cashman concluded, "This collaboration is exciting news for both organizations, and we are equally committed to the hard work ahead of us to reach our ultimate goal of establishing dermaPACE as a first-line wound healing technology with established reimbursement throughout Canada."
Source CAN-med Healthcare
Non-Hispanic Black children and low-income youth disadvantaged in concussion care